Cohort study examines Medicare Part D coverage of brand-name and generic therapies for multiple sclerosis, indicating key differences.
This cohort study examines Medicare Part D formulary coverage of disease-modifying therapies for patients with multiple sclerosis, comparing coverage of brand-name and generic drugs.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: